At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 380 enrolled
Drug / intervention
Dupilumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating Dupilumab and Placebo for Atopic Dermatitis. Completed, enrolled 380 participants across 84 sites in 7 countries.
Detailed Summary
To assess the efficacy of multiple dupilumab dose-regimens, compared to placebo, in adult participants with moderate-to-severe atopic dermatitis (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesCanada, Czechia, Germany, Hungary, Japan, Poland, United States
CollaboratorsSanofi
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2013
First PostedMay 2013
Primary CompletionMay 2014
Study CompletionSep 2014
TodayJul 2026
First PostedMay 22, 2013
Enrollment StartMay 1, 2013
Primary CompletionMay 1, 2014
Study CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 13.1 years ago
Interventions
Dupilumabdrug
Placebodrug